Salud financiera de hoja de balance de Hikma Pharmaceuticals
Salud financiera controles de criterios 4/6
Hikma Pharmaceuticals has a total shareholder equity of $2.3B and total debt of $1.2B, which brings its debt-to-equity ratio to 53.2%. Its total assets and total liabilities are $4.8B and $2.5B respectively. Hikma Pharmaceuticals's EBIT is $712.0M making its interest coverage ratio 11. It has cash and short-term investments of $260.0M.
Información clave
53.2%
Ratio deuda-patrimonio
US$1.22b
Deuda
| Ratio de cobertura de intereses | 11x |
| Efectivo | US$260.00m |
| Patrimonio | US$2.30b |
| Total pasivo | US$2.55b |
| Activos totales | US$4.85b |
Actualizaciones recientes sobre salud financiera
Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Oct 24
Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Apr 02Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Dec 27Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet
Sep 19Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Jun 21Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet
Mar 14Recent updates
Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Oct 24Hikma Pharmaceuticals PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 11Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 36% Below Their Intrinsic Value Estimate
Aug 01Is Hikma Pharmaceuticals PLC (LON:HIK) Trading At A 29% Discount?
Apr 24Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Apr 02Hikma Pharmaceuticals PLC's (LON:HIK) Share Price Matching Investor Opinion
Feb 25Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Dec 27An Intrinsic Calculation For Hikma Pharmaceuticals PLC (LON:HIK) Suggests It's 43% Undervalued
Dec 12Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet
Sep 19Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)
Sep 01Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Jun 21Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 28% Above Its Share Price
Jun 02Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet
Mar 14Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)
Feb 21Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Sep 27Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 19% Below Its Share Price
Jun 24These 4 Measures Indicate That Hikma Pharmaceuticals (LON:HIK) Is Using Debt Reasonably Well
Jun 06Here's Why Hikma Pharmaceuticals (LON:HIK) Can Manage Its Debt Responsibly
Feb 26Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 92% Above Its Share Price
Dec 01Is Hikma Pharmaceuticals (LON:HIK) Using Too Much Debt?
Nov 11Is There An Opportunity With Hikma Pharmaceuticals PLC's (LON:HIK) 32% Undervaluation?
Sep 02Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Aug 09Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 26% Below Their Intrinsic Value Estimate
May 21Hikma Pharmaceuticals (LON:HIK) Seems To Use Debt Quite Sensibly
May 03It's Unlikely That Hikma Pharmaceuticals PLC's (LON:HIK) CEO Will See A Huge Pay Rise This Year
Apr 16How Does Hikma Pharmaceuticals PLC (LON:HIK) Stand Up To These Simple Dividend Safety Checks?
Apr 13Hikma Pharmaceuticals PLC (LON:HIK) Looks Interesting, And It's About To Pay A Dividend
Mar 14Hikma Pharmaceuticals PLC Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Feb 28Análisis de la situación financiera
Pasivos a corto plazo: HIK's short term assets ($2.3B) exceed its short term liabilities ($1.4B).
Pasivo a largo plazo: HIK's short term assets ($2.3B) exceed its long term liabilities ($1.2B).
Historial y análisis de deuda-patrimonio
Nivel de deuda: HIK's net debt to equity ratio (41.9%) is considered high.
Reducción de la deuda: HIK's debt to equity ratio has increased from 34.1% to 53.2% over the past 5 years.
Cobertura de la deuda: HIK's debt is well covered by operating cash flow (47.8%).
Cobertura de intereses: HIK's interest payments on its debt are well covered by EBIT (11x coverage).